KarMMa-9
Phase 3 Clinical Trial Comparing the Efficacy and Safety of Idecabtagene Vicleucel with Lenalidomide Maintenance to Approved Lenalidomide Maintenance Alone in Patients with Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Stem Cell Transplant
What will happen during the trial?
This trial is seeking approximately 618 participants, who will be randomly assigned into one of two different groups (or cohorts), Arm A or Arm B. Participants in Arm A will receive ide-cel, an investigational autologous CAR T-cell therapy followed by lenalidomide maintenance. Participants in Arm B will receive lenalidomide maintenance.
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 3
- Enrollment
- 618 patients (estimated)
- Sponsors
- Celgene Corporation, a wholly owned subsidiary of Bristol Myers Squibb, Bristol Myers Squibb
- Collaborators
- Bristol Myers Squibb, 2Seventy Bio
- Tags
- CAR T Cell, Immunomodulatory Drug (IMiD), B-Cell Maturation Antigen (BCMA), Maintenance, Post-Autologous Stem Cell Transplant, Randomization
- Trial Type
- Treatment
- Last Update
- 1 week ago
- SparkCures ID
- 1764
- NCT Identifier
- NCT06045806
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.